Revenue, 2025

USD 5.42 Billion

Forecast, 2035

USD 12.71 Billion

CAGR, 2026-2035

8.9%

Report Coverage

Global

Photodynamic Therapy Market Trends for 2026

The global photodynamic therapy market size was estimated at USD 5.42 billion in 2025 and is predicted to increase from USD 5.9 billion in 2026 to approximately USD 12.71 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. The market is witnessing steady growth due to increasing cases of cancer and skin disorders, along with rising preference for minimally invasive and targeted treatment options. Advancements in photosensitizing agents and light-based technologies are further driving its adoption across oncology, dermatology, and often clinical applications.

Key Takeaways

• Photodynamic therapy market to crossed USD 5.9 billion by 2026.
• Market projected at USD 12.71 billion by 2035.
• CAGR of 8.9% expected in between 2026 to 2035.
• North America dominated the photodynamic therapy market with a share of 38% in 2025.
• Asia Pacific held 22% of the total market share and is expected to grow at the fastest CAGR of 10.2% in the market during the forecast period.
• By product type, the photosensitizer drugs segment dominated the market with a revenue share of 48% in 2025.
• By product type, the light source devices segment held the second-largest share of 37% of the market in 2025 and is expected to grow at the fastest CAGR of 9.3% in the market during the forecast period.
• By application, the oncology segment held a dominant share of 55% in 2025.
• By application, the dermatology segment held the second-largest share of 25% of the market in 2025 and is expected to grow at the fastest CAGR of 9.8% in the market during the forecast period.
• By end user, the hospitals segment held a dominant share of 46% in 2025.
• By end user, the specialty clinics segment held the second-largest share of 28% of the market in 2025 and is expected to grow at the fastest CAGR of 9.4% in the market during the forecast period.
• By drug type, the branded drugs segment led the photodynamic therapy market with a share of 68% in 2025.
• By drug type, the generics segment held the second-largest share of 32% of the market in 2025 and is expected to grow at the fastest CAGR of 9.7% in the market during the forecast period.
• By route of administration, the topical segment held a dominant share of 44% in 2025 and is expected to grow at the fastest CAGR of 9.2% in the market during the forecast period.

Light-Driven Precision: Fueling Growth in Photodynamic Therapy Market

Photodynamic therapy is a medical treatment that uses a light-activated drug and a specific wavelength of light to destroy abnormal or cancerous cells. The photodynamic therapy market is expanding due to the rising incidence of cancer and skin diseases, along with increasing demand for minimally invasive and targeted treatments. Advancements in photosensitizing agents, improved light delivery systems, and growing awareness of non-surgical treatment options are further boosting adoption. Its effectiveness in reducing damage to healthy tissues also supports wider clinical acceptance.

How Can AI Affect the Photodynamic Therapy Market?

AI can significantly enhance the market by improving patient selection, optimizing light dosage, and enabling precise treatment planning. It supports real-time monitoring and predictive outcomes, increasing treatment effectiveness and safety. Additionally, AI-driven drug discovery accelerates the development of advanced photosensitizers, while automation and data analytics streamline clinical workflows and expand adoption across healthcare settings.

Trend and Future Outlook of the Photodynamic Therapy Market?

• Advancements in Targeted Photosensitizers: New photosensitizers with improved selectivity and deeper tissue penetration are enhancing treatment precision and effectiveness. These innovations help minimize side effects and improve outcomes, encouraging wider adoption of photodynamic therapy across oncology and dermatology applications.
• Rising Demand for Minimally Invasive Treatments: Increasing patient preference for non-surgical and less invasive procedures is driving the adoption of photodynamic therapy. Its ability to target abnormal cells while preserving healthy tissue makes it an attractive option, especially for early-stage cancers and cosmetic dermatology.
• Expansion into Emerging Applications: Photodynamic therapy is gaining traction in new areas such as antimicrobial treatments and ophthalmology. Growing research and clinical validation are expected to broaden its therapeutic scope, creating new growth opportunities and strengthening its future market potential.

Executive Summary Table

Segmental Insights

By product Type

The Photosensitizer Drugs Segment Dominated the Market in 2025

The photosensitizer drugs segment dominated the photodynamic therapy market with a revenue share of 48% in 2025 due to their essential role in initiating the therapeutic effect by selectively accumulating in abnormal cells. Their continuous advancements, improved efficacy, and expanding clinical applications in oncology and dermatology drive strong demand. Additionally, increasing approvals and availability of novel photosensitizers further support their widespread use, making them a critical component of photodynamic therapy procedures.

The light source devices segment held the second-largest share of 37% of the market in 2025 and is expected to grow at the fastest CAGR of 9.3% in the market during the forecast period, as they are essential for activating photosensitive drugs and ensuring effective treatment outcomes. Growing adoption of advanced light technologies, including lasers and LEDs, enhances precision and safety. Increasing availability of portable and cost-effective devices, along with rising clinical use across dermatology and oncology, further drives the demand for these systems in photodynamic therapy procedures.

The optical fiber delivery systems segment held a 15% of the photodynamic therapy market share in 2025 due to its ability to deliver light precisely to internal or hard-to-reach tissues, improving treatment accuracy and effectiveness. Increasing minimally invasive procedures and expanding applications in oncology support its demand. Technological advancements in flexible and efficient fiber systems, along with rising preference for targeted therapies, further contribute to the segment’s steady growth in photodynamic therapy.

By Application Insights

The Oncology Segment Led the Market in 2025 with the Largest Share

The oncology segment held a dominant share of 55% in 2025 due to the rising global burden of cancer and the growing need for targeted, minimally invasive treatments. Photodynamic therapy offers effective tumor destruction with limited damage to surrounding healthy tissue, making it suitable for early-stage and localized cancers. Increasing clinical adoption, ongoing research, and expanding approvals for cancer indication further strengthened its leading position in the market.

The dermatology segment held the second-largest share of 25% of the photodynamic therapy market in 2025 and is expected to grow at the fastest CAGR of 9.8% in the market during the forecast period due to the high prevalence of skin conditions such as acne, psoriasis, and precancerous lesions. Photodynamic therapy is widely preferred in dermatology for its non-invasive nature, cosmetic benefits, and minimal screening. Increasing demand for aesthetic treatments, growing awareness, and the availability of outpatient procedures further support its strong adoption in dermatological applications.

The ophthalmology segment held 12% of the photodynamic therapy market share in 2025 due to increasing cases of age-related macular degeneration and other disorders. Photodynamic therapy offers a targeted, minimally invasive approach to managing abnormal blood vessel growth while preserving surrounding tissues. Rising awareness, improving clinical outcomes, and expanding use in vision-related conditions, along with advancements in light delivery techniques, are further supporting its adoption in ophthalmic care.

By End User Insights

The Hospitals Segment Led the Market in 2025 with the Largest Share

The hospitals segment held a dominant share of 46% in 2025 due to their advanced infrastructure, availability of specialized equipment, and access to skilled healthcare professionals required for photodynamic therapy procedures. Hospitals handle a higher volume of cancer and complex cases, supporting greater treatment adoption. Additionally, better reimbursement policies, multidisciplinary care, and the ability to manage complications make hospitals the primary choice for photodynamic therapy treatments.

The specialty clinics segment held the second-largest share of 28% of the photodynamic therapy market in 2025 and is expected to grow at the fastest CAGR of 9.4% in the market during the forecast period due to its strong focus on dermatology and oncology procedures, where photodynamic therapy is commonly used. These clinics provide efficient, cost-effective outpatient treatments with shorter waiting times. Their access to skilled, specialized, and patient preference for convenient, targeted care settings further contribute to the growing adoption of photodynamic therapy in specialty clinics.

The ambulatory surgical centers segment held a 16% of photodynamic therapy market share in 2025 due to the increasing demand for cost-effective, same-day procedures and minimally invasive treatments like photodynamic therapy. These centers offer hospital stays, reduced treatment costs, and faster patient turnaround. Advancements in portable light-based devices and rising preference for outpatient care settings are further encouraging the adoption of photodynamic therapy in ambulatory surgical centers.

The dermatology clinics segment held a 10% of the photodynamic therapy market share in 2025 due to the rising prevalence of skin disorders and increasing demand for aesthetic and non-invasive treatment. Photodynamic therapy is widely used for acne, actinic keratosis, and other skin conditions, offering effective results with minimal downtime. Growing awareness, improved accessibility, and patient preference for specialized skincare services further support the segment’s steady growth.

By Drug Type Insights

The Branded Drugs Segment Led the Market in 2025 with the Largest Share

The branded drugs segment led the photodynamic therapy market with a share of 68% in 2025 due to their proven clinical efficacy, strong safety profiles, and established regulatory approvals. Physicians often prefer these drugs for reliable and consistent treatment outcomes in photodynamic therapy.  Additionally, continuous innovation, patent protection, and strong marketing by key pharmaceutical companies support their widespread adoption, reinforcing their dominant position over generic alternatives in the market.

The generics segment held the second-largest share of 32% of the photodynamic therapy market in 2025 and is expected to grow at the fastest CAGR of 9.7% in the market during the forecast period due to its cost-effectiveness and increasing availability after patent expirations of branded drugs. The offer comparable therapeutic outcomes, making them attractive for price-sensitive markets and broader patient access. Growing healthcare cost pressures, supportive regulatory pathways, and rising adoption in emerging regions further contribute to the steady demand for generic photosensitizing drugs in photodynamic therapy.

By Route of Administration Insights

The Topical Segment Led the Market in 2025 with the Largest Share

The topical segment held a dominant share of 44% in 2025 and is expected to grow at the fastest CAGR of 9.2% in the market during the forecast period due to its non-invasive nature, ease of application, and strong patient compliance. It enables targeted treatment with minimal systemic side effects, making it ideal for dermatological conditions. increasing demand for outpatient care, rising aesthetic procedures, and advancements in topical formulations further accelerate its adoption and future growth.

The intravenous segment held 36% of the photodynamic therapy market share in 2025 due to delivering photosensitizing drugs systemically, making it suitable for treating deeper internal tumors. It ensures controlled dosing and higher drug concentration at the target sites, improving treatment effectiveness. Increasing use of oncology, along with advancements in drug formulation and hospital-based procedures, is further supporting the adoption of intravenous administration in photodynamic therapy.

The oral segment held a 20% of the photodynamic therapy market share in 2025 due to its convenience, ease of administration, and high patient compliance compared to invasive methods. It allows systemic delivery of photosensitizing agents, making it suitable for certain internal conditions. Growing preference for at-home or less. Complex treatment options, along with advancements in oral drug formulations and improved bioavailability, are further supporting its increasing adoption in photodynamic therapy.

Regional Insights

North America Leads: Hub of Innovation and Advanced Care

North America dominated the global photodynamic therapy market with 38% share in 2025 due to its advanced healthcare infrastructure, high adoption of innovative e-therapies, and strong presence of key market players. Rising prevalence of cancer and skin disorders, along with favorable reimbursement policies, support the widespread use of photodynamic therapy. Additionally, continuous research, early regulatory approvals, and increasing awareness among patients and physicians further strengthened the region’s leading position.

U.S. Market Trends

The U.S. photodynamic therapy market is driven by a high prevalence of cancer and dermatological conditions, along with strong adoption of advanced, minimally invasive treatments. robust healthcare infrastructure, favorable reimbursement policies, and the presence of leading pharmaceutical and medical devices companies support market growth. Continuous clinical research, early technology adoption, and increasing awareness further strengthen the country’s dominant position.

Asia Pacific Surge: Fastest-Growing Photodynamic Therapy Market

Asia Pacific captured 22% of the market share in 2025 and is anticipated to grow at the fastest CAGR of 10.2% in the market due to rising healthcare investment, increasing prevalence of cancer and skin disorders, and improving access to advanced treatments, growing awareness, expanding medical infrastructure, and a large patient population drive demand. Additionally, supportive government initiatives and increasing adoption of minimally invasive therapies further accelerate market growth across emerging economies.

India Market Trends

India is expected to grow at the fastest CAGR in the photodynamic therapy market due to its large patient population, increasing prevalence of cancer and skin disorders, and improving healthcare infrastructure. Rising awareness of minimally invasive treatments, expanding access to advanced technologies, and growing investment in healthcare further drive demand. Additionally, supportive government initiatives and the rapid expansion of specialty clinics contribute to accelerating market growth.

Supply Chain Analysis Top Vendors in the Photodynamic Therapy Market & Their Offerings

R&D

• Research and development in photodynamic therapy is centered on improving treatment precision by increasing tumor targeting, addressing oxygen limitations in tissues, and enhancing light penetration for better therapeutic outcomes. These advancements aim to expand its effectiveness in cancer and infectious disease management.
• Key players: Pfizer, Novartis, Sun Pharmaceutical Industries, and Biofrontera.

Clinical Trials

• Clinical trials in photodynamic therapy are focused on treating different cancers and pre-cancerous conditions by improving targeted tumor destruction while minimizing damage to healthy tissues through light-activated drugs. These studies aim to enhance treatment safety and effectiveness.
• Key players: Pfizer, Novartis, Amgen, and Biofrontera.

Patient Support and Services

• Patient support in photodynamic therapy mainly involves helping patients manage strong light sensitivity for a few days after treatment. It includes guidance on avoiding light exposure, use of protective measures like sunscreen and eyewear, and counseling for skin, eye, or internal conditions. Outpatient care and monitoring also ensure patient comfort and safety during and after the procedure.
• Key players: Pfizer, Novartis, Sun Pharmaceutical Industries, and Biofrontera.

Top Vendors in the Photodynamic Therapy Market & Their Offerings

SWOT Analysis

Strengths

• Minimally invasive treatment with targeted action and limited damage to healthy tissues.
• Strong effectiveness in dermatology and early-stage oncology applications.
• Growing patient preference for non-surgical procedures with faster recovery.
• Advancements in photosensitizers and light-based technologies are improving outcomes.

Weaknesses

• Limited penetration depth of light restricts use in deep-seated tumors.
• Temporary photosensitivity side effects requiring strict light avoidance.
• High initial cost of specialized equipment and treatment setup.
• Limited awareness and availability in developing regions.

Opportunities

• Expanding applications in antimicrobial, ophthalmology, and cosmetic treatments.
• Increasing healthcare investments in emerging markets like the Asia-Pacific.
• Rising demand for outpatient and minimally invasive procedures.
• Ongoing research improving drug formulations and treatment efficiency.

Threats

• Competition from alternative therapies such as chemotherapy, radiotherapy, and immunotherapy.
• Stringent regulatory approvals for new drugs and devices.
• Reimbursement challenges in certain regions.
• Variability in treatment outcomes depending on disease type and stage.

What are the Recent Developments in the Photodynamic Therapy Market?

• In September 2025, Biofrontera Inc. completed its Phase 3 clinical trial for Ameluz® topical gel used in photodynamic therapy, marking the final patient’s participation. The study focused on evaluating its effectiveness in treating actinic keratosis on areas such as the neck, trunk, and extremities.
• In September 2025, Soligenix expanded its European Medical Advisory Board by adding leading dermatology and oncology experts. This move aims to strengthen clinical guidance and research efforts for cutaneous T-cell lymphoma, while supporting the advancement of its photodynamic therapy and other targeted treatments for rare skin lymphomas.

Segments Covered in the Report

By Product Type

• Photosensitizer Drugs
  • Poephyrin-based
  • Chlorin-based
  • Phthalocyanine-based
  • Others
• Light Source Devices
  • Laser devices
  • Light Emitting Diodes (LED)
  • Lamps & Others
• Optical Fiber Delivery Systems

By Application

• Oncology
  • Skin Cancer
  • Lung Cancer
  • Esophageal Cancer
  • Head & Neck Cancer
  • Bladder Cancer
  • Others
• Dermatology
  • Acne
  • Psoriasis
  • Actinic Keratosis
• Others

By End User

• Hospitals
• Speciality Clinics
• Ambulatory Surgical Centers
• Dermatology Clinics

By Drug Type

• Branded Drugs
• Generics

By Route of Administration

• Topical
• Intravenous
• Oral

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA